A detailed history of Barclays PLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 2,065,351 shares of CHRS stock, worth $3.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,065,351
Previous 3,484,395 40.73%
Holding current value
$3.57 Million
Previous $11.6 Million 57.45%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.02 - $3.14 $2.87 Million - $4.46 Million
-1,419,044 Reduced 40.73%
2,065,351 $4.94 Million
Q4 2023

Feb 15, 2024

BUY
$1.59 - $3.85 $1.76 Million - $4.27 Million
1,108,838 Added 46.68%
3,484,395 $11.6 Million
Q3 2023

Nov 07, 2023

BUY
$3.74 - $5.45 $8.61 Million - $12.5 Million
2,301,444 Added 3105.32%
2,375,557 $8.88 Million
Q2 2023

Aug 03, 2023

SELL
$3.79 - $8.3 $433,587 - $949,544
-114,403 Reduced 60.69%
74,113 $317,000
Q1 2023

May 04, 2023

SELL
$5.89 - $10.52 $650,786 - $1.16 Million
-110,490 Reduced 36.95%
188,516 $1.29 Million
Q4 2022

Feb 13, 2023

BUY
$5.69 - $10.07 $536,009 - $948,614
94,202 Added 46.0%
299,006 $2.37 Million
Q3 2022

Nov 03, 2022

BUY
$7.17 - $13.87 $1.16 Million - $2.25 Million
162,448 Added 383.53%
204,804 $1.97 Million
Q2 2022

Aug 12, 2022

SELL
$5.86 - $13.23 $70,929 - $160,135
-12,104 Reduced 22.23%
42,356 $308,000
Q1 2022

May 16, 2022

SELL
$10.92 - $16.41 $461,151 - $692,994
-42,230 Reduced 43.68%
54,460 $705,000
Q4 2021

Feb 14, 2022

SELL
$15.81 - $18.99 $561,776 - $674,771
-35,533 Reduced 26.87%
96,690 $1.54 Million
Q3 2021

Nov 09, 2021

BUY
$12.68 - $17.79 $313,918 - $440,427
24,757 Added 23.04%
132,223 $2.13 Million
Q2 2021

Aug 13, 2021

SELL
$12.95 - $15.41 $532,478 - $633,628
-41,118 Reduced 27.67%
107,466 $1.49 Million
Q1 2021

May 13, 2021

SELL
$14.42 - $21.39 $7.13 Million - $10.6 Million
-494,432 Reduced 76.89%
148,584 $2.17 Million
Q4 2020

Feb 11, 2021

BUY
$16.56 - $18.94 $5 Million - $5.71 Million
301,709 Added 88.4%
643,016 $11.2 Million
Q3 2020

Nov 12, 2020

BUY
$17.41 - $19.89 $981,819 - $1.12 Million
56,394 Added 19.79%
341,307 $6.26 Million
Q2 2020

Aug 12, 2020

SELL
$14.43 - $19.16 $1.79 Million - $2.38 Million
-124,055 Reduced 30.33%
284,913 $5.09 Million
Q1 2020

May 13, 2020

BUY
$11.67 - $22.53 $3.9 Million - $7.52 Million
333,856 Added 444.48%
408,968 $6.63 Million
Q4 2019

Feb 10, 2020

SELL
$16.33 - $21.37 $197,723 - $258,747
-12,108 Reduced 13.88%
75,112 $1.35 Million
Q3 2019

Nov 14, 2019

BUY
$16.3 - $23.37 $771,234 - $1.11 Million
47,315 Added 118.57%
87,220 $1.77 Million
Q2 2019

Aug 14, 2019

BUY
$13.1 - $22.1 $257,048 - $433,646
19,622 Added 96.74%
39,905 $882,000
Q1 2019

May 15, 2019

BUY
$8.38 - $15.5 $148,217 - $274,148
17,687 Added 681.32%
20,283 $276,000
Q4 2018

Feb 14, 2019

SELL
$8.65 - $16.28 $665,833 - $1.25 Million
-76,975 Reduced 96.74%
2,596 $23,000
Q3 2018

Nov 14, 2018

BUY
$14.45 - $20.25 $822,985 - $1.15 Million
56,954 Added 251.82%
79,571 $1.31 Million
Q2 2018

Aug 14, 2018

BUY
$10.25 - $17.45 $125,511 - $213,675
12,245 Added 118.06%
22,617 $317,000
Q1 2018

May 15, 2018

BUY
$9.1 - $13.7 $25,416 - $38,264
2,793 Added 36.85%
10,372 $115,000
Q4 2017

Feb 14, 2018

SELL
$8.35 - $14.4 $8,851 - $15,264
-1,060 Reduced 12.27%
7,579 $67,000
Q3 2017

Nov 14, 2017

BUY
$11.1 - $14.5 $95,892 - $125,265
8,639
8,639 $115,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $134M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.